Barclays Raises Humana (NYSE:HUM) Price Target to $270.00

Humana (NYSE:HUM) had its price objective boosted by research analysts at Barclays from $255.00 to $270.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s price objective indicates a potential upside of 5.35% from the stock’s previous close.

HUM has been the topic of several other research reports. Wells Fargo & Company cut their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday. Finally, TD Cowen lifted their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $293.05.

Humana Stock Performance

Shares of HUM stock traded down $3.74 on Thursday, hitting $256.30. 152,879 shares of the stock traded hands, compared to its average volume of 1,638,022. The company’s fifty day moving average is $272.44 and its 200 day moving average is $295.47. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a market capitalization of $30.86 billion, a PE ratio of 22.70, a PEG ratio of 2.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, equities research analysts predict that Humana will post 16.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Trading of Humana

Several institutional investors have recently made changes to their positions in HUM. Creative Financial Designs Inc. ADV lifted its position in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares in the last quarter. FPC Investment Advisory Inc. acquired a new stake in shares of Humana during the 4th quarter valued at about $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the 4th quarter valued at approximately $30,000. Ashton Thomas Securities LLC acquired a new position in Humana in the third quarter worth approximately $31,000. Finally, Your Advocates Ltd. LLP raised its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.